# PrIME Biologics Private

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/prime-biologics-private

- Industry: Biopolymers
- Headquarters: Singapore, Singapore
- Website: www.primebiologics.com
- Total disclosed funding: $13M
- Latest round: Series A (May 9, 2014)
- Investors on record: 2

## About

PrIME Biologics is a Singapore-based company specializing in the development of innovative biological solutions that address diverse health and wellness needs through advanced proprietary technologies.Founded in 2010 in Singapore, PrIME Biologics specializes in biological solutions for health applications. The company raised SGD 16 mn in Series A funding in May 2014 from investors including Xeraya Capital and JP Asia Capital, marking its first significant funding round.PrIME Biologics specializes in innovative biological solutions that cater to a diverse range of industries. The company’s core offerings focus on advanced biological products designed to address specific health and wellness needs. These products are developed through proprietary technologies that enhance their efficacy and usability in both clinical and everyday settings. The end-use cases include applications in regenerative medicine, therapeutic treatments, and enhanced biological functionalities. PrIME Biologics serves a broad client base that includes healthcare providers, research institutions, and end consumers across North America, Europe, and Asia. Their products are strategically marketed to various sectors, emphasizing their unique benefits in improving health outcomes and optimizing biological processes.In 2016, PrIME Biologics reported a revenue of SGD 246,404.30 and an EBITDA of -SGD 10,406,369.40, indicating the financial performance for that fiscal year.PrIME Biologics aims to leverage its recent SGD 16 mn funding from May 2014 to enhance product development and expand into new markets. The company plans to introduce new biological products tailored for emerging healthcare needs, with launches anticipated by 2025. Targeted expansion includes entering additional markets in Asia and Europe, focusing specifically on regions that show demand for advanced therapeutic solutions.

## Funding rounds

- Series A, May 9, 2014, $13M — JP Asia Capital, Xeraya Capital

## Investors

- JP Asia Capital — Series A
- Xeraya Capital (https://capitalatlas.ai/funds/xeraya-capital) — Series A